64 Advanced Solid Tumors Clinical Trials in Fairfax, VA (2026)

Q: How do I join a clinical trial in Fairfax?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Fairfax research site will contact you.

Recruiting Advanced Solid Tumors Studies in Fairfax

NCT05067283Recruiting

A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)

This is a study evaluating the safety, pharmacokinetics, and efficacy of calderasib alone, and calderasib plus other combination therapies in participants with advanced solid tumors with identified ki...

Fairfax, VAPHASE1830 participantsMerck Sharp & Dohme LLC

View Study Details

NCT06983743Recruiting

A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors

The main purpose of the study is to assess whether the study drug, ERAS-0015, is safe and tolerable when administered to patients with advanced or metastatic solid tumors with certain RAS mutations. E...

Fairfax, VAPHASE1600 participantsErasca, Inc.

View Study Details

NCT06589596Recruiting

An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors

This is an open-label, multicenter, first-in-human dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity...

Fairfax, VAPHASE1525 participantsBeOne Medicines

View Study Details

NCT06892379Recruiting

A Study of HS-20110 in Participants With Advanced Solid Tumors

This is an open-label, multicenter study to evaluate the safety and tolerability of HS-20110 in participants with advanced solid malignant tumors...

Fairfax, VAPHASE1475 participantsHansoh BioMedical R&D Company

View Study Details

NCT07094113Recruiting

AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors

The purpose of this first-in-human study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AMG 410 when administered alone or in combin...

Fairfax, VAPHASE1434 participantsAmgen

View Study Details

NCT07287995Recruiting

A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors

Specific proteins found in tumors help the tumors spread and grow. People with solid tumors often have a protein called TROP2 in their tumor. ASP2998 is being developed to attach to TROP2 and then att...

Fairfax, VAPHASE1428 participantsAstellas Pharma Global Development, Inc.

View Study Details

NCT07066657Recruiting

A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors

This is an open-label, multi-center, phase I study to evaluate the safety, tolerability, efficacy, and pharmacokinetics of MRG007 (ARR-217) in patients with unresectable locally advanced or metastatic...

Fairfax, VAPHASE1405 participantsArriVent BioPharma, Inc.

View Study Details

NCT07397338Recruiting

Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RAS(ON) inhibitors in combination with ivonescimab in adults with advanc...

Fairfax, VAPHASE1370 participantsRevolution Medicines, Inc.

View Study Details

NCT06130553Recruiting

A Study of AZD3470, a PRMT5 Inhibitor, in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors

This is a first time in human (FTiH) Phase I/IIa, open-label, multi-centre study of AZD3470 in participants with advanced or metastatic solid tumors with MTAP deficiency. The study consists of several...

Fairfax, VAPHASE1334 participantsAstraZeneca

View Study Details

NCT05320588Recruiting

A Study in Patients With Advanced Cancers

A first-in-human study using BIO-106 as a single agent and in combination with pembrolizumab in advanced cancers....

Fairfax, VAPHASE1332 participantsBiOneCure Therapeutics Inc.

View Study Details

NCT07136779Recruiting

First-in-Human Trial of VBC101 in Participants With Advanced Solid Tumor Malignancies

This is a multicenter, open-label, multiple-dose, FIH Phase 1/2a trial. The Phase 1 portion adopts an accelerated titration for the first dose level, followed by BOIN design to identify the MTD and/or...

Fairfax, VAPHASE1310 participantsVelaVigo Bio Inc

View Study Details

NCT05954312Recruiting

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors

A FIH dose escalation and dose expansion study to evaluate VVD-130037 in participants with advanced solid tumors as a single agent, and in combination with docetaxel, paclitaxel, or pembrolizumab....

Fairfax, VAPHASE1290 participantsVividion Therapeutics, Inc.

View Study Details

NCT05753722Recruiting

A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies

The goal of this Open-Label Study is to evaluate the safety and tolerability of PRTH-101 alone or in combination with pembrolizumab in adults with advance or metastatic solid tumors....

Fairfax, VAPHASE1270 participantsIncendia Therapeutics

View Study Details

NCT07629960Recruiting

A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations

A first in human study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of BLU-924 / SAR449336, a pan-KRAS inhibitor, in participants with advanced Pancreatic Cancer, Non...

Fairfax, VAPHASE1265 participantsBlueprint Medicines Corporation

View Study Details

NCT06480552Recruiting

An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

The primary objectives of this trial are to: * Characterize the safety and tolerability of TEV-56278 * Determine the Recommended Phase 2 Dose (RP2D) * Evaluate antitumor activity of TEV-56278 (Part 2...

Fairfax, VAPHASE1240 participantsTeva Branded Pharmaceutical Products R&D LLC

View Study Details

NCT06707610Recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors

TThis is a first-in-human (FIH), open-label, multicenter dose escalation and expansion study of ALK202. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and an...

Fairfax, VAPHASE1234 participantsShanghai Allink Biotherapeutics Co., Ltd.

View Study Details

NCT07141706Recruiting

A Study of DB-1317 in Selected Advanced/Metastatic Solid Tumors

This is a multicenter, open-label, multiple-dose, FIH Phase 1a/1b study. Phase 1a adopts an accelerated titration design and a BOIN design to identify the MTD or MAD of DB-1317; Phase 1b includes up t...

Fairfax, VAPHASE1233 participantsDualityBio Inc.

View Study Details

NCT06804824Recruiting

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors

A FIH study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of VVD-159642, a rat sarcoma viral oncogene-phosphatidylinositol 3-k...

Fairfax, VAPHASE1220 participantsVividion Therapeutics, Inc.

View Study Details

NCT06795412Recruiting

Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors

The primary objective of this study is to determine the recommended Phase 2 doses (RP2D(s)) and maximum tolerated dose (MTD) of PYX-201 in combination with pembrolizumab for participants with advanced...

Fairfax, VAPHASE1220 participantsPyxis Oncology, Inc

View Study Details

NCT05907980Recruiting

A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors

This is a Phase Ia/Ib open-label, dose-escalation study to evaluate the safety and pharmacokinetics of ROSE12 as a single agent and in combination with other anti-tumor agents in patients with locally...

Fairfax, VAPHASE1219 participantsChugai Pharmaceutical

View Study Details

NCT07182591Recruiting

A Study of DS5361b in Participants With Advanced Solid Tumors

This study aims to assess the safety, tolerability, and preliminary efficacy and to determine the MTD of DS5361b in monotherapy and combination with pembrolizumab in participants with advanced or meta...

Fairfax, VAPHASE1192 participantsDaiichi Sankyo

View Study Details

NCT07169734Recruiting

A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic, preliminary anti-tumor activity, and to determine the recommended Phase II dose (RP2D) of the ALE.P...

Fairfax, VAPHASE1180 participantsAlentis Therapeutics AG

View Study Details

NCT07374848Recruiting

Phase 1a/b Study of ZL-6201 Safety, PK, and Preliminary Efficacy in Sarcoma and Selected Tumors

The purpose of this study is to evaluate the safety and tolerability of investigational study drug ZL-6201 for treating sarcoma and solid tumors cancer....

Fairfax, VAPHASE1180 participantsZai Lab (Shanghai) Co., Ltd.

View Study Details

NCT07128303Recruiting

Study of GS-5319 in Adults With Solid Tumors

The goal of this clinical study is to learn more about the study drug, GS-5319, its dosing, safety and tolerability in adults with solid tumors, where the participants show a specific gene alteration ...

Fairfax, VAPHASE1178 participantsGilead Sciences

View Study Details

NCT06108050Recruiting

JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors

This Phase 1 first-in-human study will investigate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and preliminary antitumor activity of JZP898 monotherapy as well as JZP898 in combin...

Fairfax, VAPHASE1177 participantsJazz Pharmaceuticals

View Study Details

NCT06747585Recruiting

A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors

Fairfax, VAPHASE1170 participantsAlentis Therapeutics AG

View Study Details

NCT06265688Recruiting

First In Human Study of CX-2051 in Advanced Solid Tumors

The purpose of this first-in-human study, CTMX-2051-101, is to characterize the safety, tolerability, and antitumor activity of CX-2051 as a monotherapy and in combination with bevacizumab in adult pa...

Fairfax, VAPHASE1160 participantsCytomX Therapeutics

View Study Details

NCT07612176Recruiting

A Phase 1 Study of NEOK001, a B7-H3 and ROR1 Targeting Bispecific ADC in Participants With Select Solid Tumors

This is a first in human (FIH), Phase 1, dose escalation and expansion study in select solid tumors. This study includes 2 parts: a Dose Escalation and Backfill portion (Part A) and a Dose Expansion p...

Fairfax, VAPHASE1155 participantsNEOK Bio, Inc.

View Study Details

NCT07612189Recruiting

A Study of NEOK002, an EGFR and MUC1 Targeting Bispecific ADC, in Participants With Select Solid Tumors

This is a first in human (FIH), Phase 1 dose escalation and expansion study in select solid tumors. This study includes 2 parts: a Dose Escalation and Backfill portion (Part A) and a Dose Expansion po...

Fairfax, VAPHASE1155 participantsNEOK Bio, Inc.

View Study Details

NCT06532565Recruiting

Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid Tumors

The main goal of this first-in-human (FIH) study is to learn about the safety and dosing of GS-2121 when given alone or in combination with zimberelimab (ZIM) in participants with advanced solid tumor...

Fairfax, VAPHASE1154 participantsGilead Sciences

View Study Details

NCT06598800Recruiting

Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors

This is a first-in-human (FIH), Phase 1a/1b, open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and prelim...

Fairfax, VAPHASE1153 participantsBeOne Medicines

View Study Details

NCT07145255Recruiting

Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors

This is a multicenter, open-label FIH, Phase 1a (dose escalation), Phase 1b (dose expansion) and Phase 2 study in patients with advanced metastatic solid tumors refractory to standard treatment....

Fairfax, VAPHASE1150 participantsMBrace Therapeutics

View Study Details

NCT07524348Recruiting

A Trial to Investigate the Safety of E303 in Participants With Advanced Refractory Solid Tumors

This is a Phase I trial to evaluate the safety, tolerability and efficacy of nectin-4 targeting antibody-drug conjugate (SBE303) in participants with advanced solid tumors...

Fairfax, VAPHASE1149 participantsSamsung Bioepis Co., Ltd.

View Study Details

NCT06781983Recruiting

Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors

This is a first-in-human, open-label, multicenter, Phase 1 study to evaluate the safety, tolerability and preliminary efficacy of IPH4502 and to determine the recommended Phase 2 dose (RP2D) in advanc...

Fairfax, VAPHASE1145 participantsInnate Pharma

View Study Details

NCT05856981Recruiting

Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors

This first-in-human, open-label, multicenter, multi-arm dose-escalation study is designed to evaluate the safety, PK, and PD of ADU-1805, an anti- SIRPα monoclonal antibody, as monotherapy and in comb...

Fairfax, VAPHASE1130 participantsSairopa B.V.

View Study Details

NCT06270706Recruiting

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

This is a Phase 1a/1b, dose-escalation/expansion, consecutive-cohort, open-label study to evaluate the safety, tolerability, PK, PD, and preliminary evidence of antitumor activity of PLN-101095 in com...

Fairfax, VAPHASE1124 participantsPliant Therapeutics, Inc.

View Study Details

NCT06797336Recruiting

A Study of PT0253 in Participants With KRAS G12D Mutated Advanced Solid Tumors

The primary purpose of this study is to evaluate the safety and tolerability, determine the maximally tolerated dose (MTD) and/or recommended Phase 2 dose(s) (RP2D) of PT0253 in adult participants wit...

Fairfax, VAPHASE1115 participantsPAQ Therapeutics, Inc.

View Study Details

NCT07213817Recruiting

A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours

This study aims to find the right dosage and evaluate the safety and effectiveness of the drug IPN60300 in adults with advanced solid tumours, which are cancers that have spread to other parts of the ...

Fairfax, VAPHASE1114 participantsIpsen

View Study Details

NCT05765851Recruiting

A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors

This study will evaluate the safety and efficacy of DS-1103a combination therapy in participants with advanced solid tumors....

Fairfax, VAPHASE1108 participantsDaiichi Sankyo

View Study Details

NCT06975293Recruiting

STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers

This early phase oncology trial will be conducted at various study centers to investigate the safety, tolerability, and antitumor activity of STC-15 (a METTL3 inhibitor) in combination with toripalima...

Fairfax, VAPHASE1107 participantsSTORM Therapeutics LTD

View Study Details

NCT07213830Recruiting

A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies

The purpose of this study is to determine the appropriate dosage, safety and effectiveness of a new drug, IPN01203, in adults with advanced solid tumours. Advanced solid tumours are cancers that can ...

Fairfax, VAPHASE1102 participantsIpsen

View Study Details

NCT07361562Recruiting

A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors

This is an open-label, phase 1/1b study evaluating the safety, tolerability, pharmacokinetic (what the body does to the drug), pharmacodynamic (what the drug does to the body), and antitumor activity ...

Fairfax, VAPHASE1100 participantsCogent Biosciences, Inc.

View Study Details

NCT06507306Recruiting

A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

The goal of this clinical trial is to learn if KQB198 works to treat advanced solid tumor cancer in adults. It will also learn about the safety of KQB198. The main questions it aims to answer are: * ...

Fairfax, VAPHASE1100 participantsKumquat Biosciences Inc.

View Study Details

NCT06106360Recruiting

A Pilot Prospective Clinical Trial Using Remote Monitoring for Cancer Patients Undergoing Outpatient Chemotherapy

A pilot study using remote monitoring technology developed by Locus Health in cancer patients undergoing chemotherapy treatment....

Fairfax, VA100 participantsInova Health Care Services

View Study Details

NCT07095868Recruiting

Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 Alone and in Combination in Patients With Selected Solid Tumors

Brief Summary: The purpose of this clinical trial is to evaluate the safety, tolerability, preliminary efficacy, and immunogenicity of EVM14 administered intramuscularly (IM) alone and in combination...

Fairfax, VAPHASE194 participantsEverest Medicines (Beijing) Co., Ltd.

View Study Details

NCT06799065Recruiting

First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer

The goal of this study is to identify a safe and tolerated dose of the orally administered KIF18A inhibitor ATX-295. In addition, this study will evaluate the pharmacokinetics, pharmacodynamics and pr...

Fairfax, VAPHASE190 participantsAccent Therapeutics

View Study Details

NCT05103683Recruiting

First in Human Study of TORL-1-23 in Participants With Advanced Cancer

This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-1-23 in patients with advanced cancer...

Fairfax, VAPHASE190 participantsTORL Biotherapeutics, LLC

View Study Details

NCT06136884Recruiting

A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors With or Without Brain Metastases

The purpose of this study is to assess the safety, tolerability and efficacy of the study drug AO-252 and identify the best dose for use in future studies....

Fairfax, VAPHASE186 participantsA2A Pharmaceuticals Inc.

View Study Details

NCT06833008Recruiting

A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours

The purpose of this study is to determine the appropriate dosage, safety and effectiveness of a new study drug IPN01195 in adults with advanced solid tumours. The participants in this study will have...

Fairfax, VAPHASE185 participantsIpsen

View Study Details

NCT06816992Recruiting

ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC

The purpose of this study is to establish the recommended phase 2 dose (RP2D), safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of ORIC-114 in combination with ...

Fairfax, VAPHASE176 participantsORIC Pharmaceuticals

View Study Details

NCT06710379Recruiting

A Study of ADRX-0405 in Subjects With Select Advanced Solid Tumors

The primary purpose of this study is to assess the safety, tolerability, and pharmacokinetics, and to identify the optimal dose of ADRX-0405 in patients with select advanced solid tumors....

Fairfax, VAPHASE168 participantsAdcentrx Therapeutics

View Study Details

NCT05329103Recruiting

A Study to Evaluate PEEL-224 in Patients With Advanced Solid Tumors

This is a first-in-human, dose escalation, repeat-dose, multi-center, open-label study evaluating safety, tolerability, PK, and preliminary antitumor activity of PEEL-224 in patients with advanced sol...

Fairfax, VAPHASE165 participantsPeel Therapeutics Inc

View Study Details

NCT06307795Recruiting

A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors

This is a Phase 1, first-in-human, open-label, multi-center study with the aim of exploring the safety, tolerability, PK, and preliminary anti-tumor activity of ANS014004 as a single agent in particip...

Fairfax, VAPHASE163 participantsAvistone Biotechnology Co., Ltd.

View Study Details

NCT07181681Recruiting

A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors

This study is a first-in-human (FIH), Phase 1a/1b study of BG-C0902, a fully humanized anti-epidermal growth factor receptor (EGFR) and anti-mesenchymal-epithelial transition (MET) antibody, conjugate...

Fairfax, VAPHASE163 participantsBeOne Medicines

View Study Details

NCT07115043Recruiting

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors...

Fairfax, VAPHASE160 participantsAstraZeneca

View Study Details

NCT06600789Recruiting

A Modular Phase 1/2 Study with CT7439 in Participants with Solid Malignancies

This modular, multi-part, multi-arm, Phase 1/2, FIH study allows the evaluation of the safety and tolerability of CT7439, dosed as a monotherapy and in combination with anticancer treatment in partici...

Fairfax, VAPHASE150 participantsCarrick Therapeutics Limited

View Study Details

NCT06959706Recruiting

Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors

The primary objectives of this study are to evaluate the safety and tolerability of TGW101 and determine the recommended dosing regimen(s) for further study. The secondary objectives are to assess pha...

Fairfax, VAPHASE150 participantsTagworks Pharmaceuticals BV

View Study Details

NCT06187402Recruiting

A Study of LM-24C5 For Advanced Solid Tumors

To assess the safety and tolerability, obtain the recommended phase 2 dose (RP2D)/optimal biologic dose (OBD) and/or Maximum Tolerated Dose (MTD) for LM-24C5 in subjects with advanced solid tumors....

Fairfax, VAPHASE149 participantsLaNova Medicines Limited

View Study Details

NCT07161414Recruiting

A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy

The purpose of this study is to determine the subcutaneous (SC) dose that gives rilvegostomig exposure comparable to the intravenous (IV) exposure, and to evaluate the pharmacokinetics (PK) and safety...

Fairfax, VAPHASE140 participantsAstraZeneca

View Study Details

NCT07312903Recruiting

DPTX3186 in Wnt Pathway Activated Solid Tumors

This is a first-in human clinical study of DPTX3186 in subjects with Wnt-pathway activated solid tumors where no other treatments exist. The study will evaluate safety, pharmacokinetics, and initial a...

Fairfax, VAPHASE140 participantsDewpoint Therapeutics

View Study Details

NCT07356453Recruiting

A Study of PARG Inhibitor FORX-428 in Patients With Advanced Solid Tumors.

The goal of this interventional study is to evaluate the safety and tolerability of escalating doses of FORX-48 as monotherapy in patients with select advanced solid tumors with BRCA1/2 mutations or o...

Fairfax, VAPHASE140 participantsFoRx Therapeutics AG

View Study Details

NCT05431270Recruiting

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

This is a first-in-human, Phase 1/2, open-label, study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Mavrostobart (PT199) alone and in ...

Fairfax, VAPHASE140 participantsPhanes Therapeutics

View Study Details

NCT04999384Recruiting

First in Human, Dose Escalation Study of AN4005

Open-label, multicenter, phase 1 study to investigate the safety, tolerability, and PK of AN4005 in patients with advanced tumors. This study is a first-in-human, dose escalation study with the object...

Fairfax, VAPHASE131 participantsAdlai Nortye Biopharma Co., Ltd.

View Study Details

NCT04370587Recruiting

A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

This is a Phase 1/2a, open-label, study to evaluate the safety and preliminary efficacy of intratumoral T3011 given alone and in combination with intravenous pembrolizumab in partients with advanced o...

Fairfax, VAPHASE130 participantsImmVira Pharma Co. Ltd

View Study Details

About Advanced Solid Tumors Clinical Trials in Fairfax

Advanced solid tumors refer to cancers that have grown beyond the original site or spread to distant organs. Many clinical trials enroll patients with various types of advanced solid tumors to test novel therapies. These trials often investigate immunotherapy, targeted therapy, and combination approaches.

There are currently 64 advanced solid tumors clinical trials recruiting participants in Fairfax, VA. These studies are seeking a combined 11,842 participants. Research is being sponsored by Merck Sharp & Dohme LLC, Erasca, Inc., BeOne Medicines and 50 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Advanced Solid Tumors Clinical Trials in Fairfax — FAQ

Are there advanced solid tumors clinical trials in Fairfax?

Yes, there are 64 advanced solid tumors clinical trials currently recruiting in Fairfax, VA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Fairfax?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Fairfax research site will contact you about next steps.

Are clinical trials in Fairfax free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Fairfax studies also compensate for your time and travel.

What advanced solid tumors treatments are being tested?

The 64 active trials in Fairfax are testing new therapies including novel drugs, biologics, and treatment approaches for advanced solid tumors.

Data updated July 19, 2026 from ClinicalTrials.gov